-
Product Insights
NewNet Present Value Model: Akeso Inc’s Ivonescimab
Empower your strategies with our Net Present Value Model: Akeso Inc's Ivonescimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Akeso – Shanghai Global R&D Center – Shanghai
The Akeso – Shanghai Global R&D Center – Shanghai project involves the construction of a global research and development (R&D) center at the Zhangjiang Headquarters Park in Shanghai, China. Equip yourself with the essential tools needed to make informed and profitable decisions with our Akeso – Shanghai Global R&D Center – Shanghai report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding...
-
Product Insights
NewNet Present Value Model: Akeso Inc’s Ligufalimab
Empower your strategies with our Net Present Value Model: Akeso Inc's Ligufalimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Akeso Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Akeso Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Breast Cancer Drug Details: AGEN-2373 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Ovarian Cancer Drug Details: Dresbuxelimab (AK-119) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Pancreatic Ductal Adenocarcinoma Drug Details: Dresbuxelimab (AK-119) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Kidney Cancer (Renal Cell Cancer) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Non-Small Cell Lung Cancer Drug Details: Dresbuxelimab (AK-119)...